<SEC-DOCUMENT>0000899243-23-000829.txt : 20230105
<SEC-HEADER>0000899243-23-000829.hdr.sgml : 20230105
<ACCEPTANCE-DATETIME>20230105063026
ACCESSION NUMBER:		0000899243-23-000829
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230101
FILED AS OF DATE:		20230105
DATE AS OF CHANGE:		20230105

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Selnick Jesse
		CENTRAL INDEX KEY:			0001870424

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40587
		FILM NUMBER:		23509684

	MAIL ADDRESS:	
		STREET 1:		C/O SIGHT SCIENCES, INC.
		STREET 2:		4040 CAMPBELL AVENUE, SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sight Sciences, Inc.
		CENTRAL INDEX KEY:			0001531177
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				800625749
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		3000 SAND HILL ROAD
		STREET 2:		BUILDING 3, SUITE 105
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		(415) 889-0550

	MAIL ADDRESS:	
		STREET 1:		3000 SAND HILL ROAD
		STREET 2:		BUILDING 3, SUITE 105
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-01-01</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001531177</issuerCik>
        <issuerName>Sight Sciences, Inc.</issuerName>
        <issuerTradingSymbol>SGHT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001870424</rptOwnerCik>
            <rptOwnerName>Selnick Jesse</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SIGHT SCIENCES, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>4040 CAMPBELL AVE., SUITE 100</rptOwnerStreet2>
            <rptOwnerCity>MENLO PARK</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94025</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Financial Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2023-01-01</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>28100</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>406250</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2023-01-04</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>F</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>2891</value>
                    <footnoteId id="F3"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>12.379</value>
                    <footnoteId id="F4"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>403359</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Reflects a grant of restricted stock units (&quot;RSUs&quot;) made to the Reporting Person on February 9, 2022 under the Issuer's 2021 Incentive Award Plan (such grant, the &quot;2022 RSU Grant&quot;), as reported in Table II on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on February 11, 2022. Of the RSUs awarded to the Reporting Person under the 2022 RSU Grant, 25% vested on January 1, 2023, and an additional 25% vest on each of January 1, 2024, 2025, and 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share (&quot;Common Stock&quot;). The RSUs have no expiration date.</footnote>
        <footnote id="F2">Includes 7,025 shares of Common Stock issued in connection with the January 1, 2023 vesting of the 2022 RSU Grant.</footnote>
        <footnote id="F3">Reflects shares of Common Stock sold to cover the Reporting Person's tax liability in connection with the vesting of RSUs.</footnote>
        <footnote id="F4">Reflects the weighted average price at which the shares were sold. The shares were sold in multiple transactions at prices ranging from $12.16 to $12.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Jeremy Hayden, Attorney-in-Fact for Jesse Selnick</signatureName>
        <signatureDate>2023-01-04</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
